


# SARS-CoV-2

Solutions for the COVID-19 diagnosis



CerTest  
BIOTEC



# About the virus

In December 2019, certain individuals working or living in the vicinity of the Huanan seafood market in Wuhan, in the province of Hubei, China, developed pneumonia of unknown cause.

Massive sequencing analysis of the respiratory samples revealed a new coronavirus, initially known as 2019 new coronavirus (2019-nCoV) and subsequently renamed as SARS-CoV-2.


**CerTest has been working urgently and determinedly since the start of the spread of the virus to collaborate in the global response to this serious disease.**

The coronaviruses (CoV) are RNA, enveloped viruses, with a large genome (29.9 kb), of which the  $\beta$ -CoV and  $\alpha$ -CoV are able to infect mammals.

The viruses belonging to the *Coronaviridae* family contain a higher abundance of the membrane protein (M) abundant among other proteins, that is, the peak glycoprotein (S), the nucleocapsid protein (N) and an envelope protein (E).

The spike glycoprotein (S) is one of the targets of the T-cell response in the immune system. The S protein also facilitates the fusion of the viral envelope to the receptor ACE2 and the entrance of the virus in the target cell. The ACE2 receptors are present in the cells of the arteries, veins, smooth muscles, small intestine, lung alveoli, hair follicles, cardiac myofibroblasts, skin, brain and kidney.

Consequently, the SARS-CoV-2 can potentially infect these tissues.





## Symptoms


The clinical forms of this disease range from mild to very severe symptoms: **pneumonia, a temperature and respiratory symptoms are the most common.** Other symptoms of the viral infection include a sore throat, aches and pains, or difficulty breathing. In some cases there may be nasal secretion, nausea and diarrhea.

The recently discovered outbreak of coronavirus starts mainly with nasal secretions or drops of saliva, once an infected individual sneezes or coughs. The estimated incubation time is 2 weeks. Due to the high rate of SARS-CoV-2 infection, the detection of asymptomatic positive patients is probably one of the key factors for controlling the outbreak.

## Did you know?

**Human-to-human transmission of the SARS-CoV-2 has been confirmed, even in the incubation period without symptoms,** and the virus could cause severe respiratory illness like those SARS-CoV produced.

CDC -Centers of Disease Control and Prevention- recommends **upper respiratory tract specimens** (nasopharyngeal (NP) swab, oropharyngeal (OP) swabs, nasal mid-turbinate swab, nasal swab, nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimens collected mainly by a healthcare provider) **and/or lower respiratory specimens** (sputum, endotracheal aspirate, or bronchoalveolar lavage in patients with more severe respiratory disease) for the identification of SARS-CoV-2 and other respiratory viruses, such as Influenza and RSV.



“ On March 11, the WHO declared the disease a pandemic, due to the high number of individuals infected and the rapid spread of the disease around the world.

# CerTest bioSCIENCE

## Raw materials

Highly sensitive and specific high quality recombinant proteins and monoclonal antibodies for the development of diagnosis assays for SARS-CoV-2 and other coronaviruses.



### Suitable for Lateral Flow, CLIA and ELISA assay!

#### Monoclonal antibodies for SARS-CoV-2 detection (Nucleoprotein detection)

	MT-16CV01	Anti SARS-CoV-2 mAb (clone CV01) (x1mg) / Paired with MT-16CV15, MT-16CV40 & MT-16CV74
	MT-16CV10	Anti SARS-CoV-2 mAb (clone CV10) (x1mg) / Paired with MT-16CV15, MT-16CV40 & MT-16CV74
	MT-16CV15	Anti SARS-CoV-2 mAb (clone CV15) (x1mg) / Paired with MT-16CV01 & MT-16CV10
	MT-16CV40	Anti SARS-CoV-2 mAb (clone CV40) (x1mg) / Paired with MT-16CV01 & MT-16CV10
	MT-16CV74	Anti SARS-CoV-2 mAb (clone CV74) (x1mg) / Paired with MT-16CV01 & MT-16CV10

#### Antigens. Mammalian expression

	MT-25C19NPm	SARS-CoV-2 recombinant Nucleoprotein (N) (full sequence) (x1mg)
	MT-25C19S	SARS-CoV-2 recombinant Spike Glycoprotein (S) (full sequence) (x1mg)
	MT-25C19S.b.1.1.7	SARS-CoV-2 recombinant Spike Glycoprotein (S) <b>UK variant</b> (x1mg)
	MT-25C19S.1.351	SARS-CoV-2 recombinant Spike Glycoprotein (S) <b>South Africa variant</b> (x1mg)
	MT-25C19S.p.1	SARS-CoV-2 recombinant Spike Glycoprotein (S) <b>Brazilian variant</b> (x1mg)
	MT-25C19S.b.1.617.2	SARS-CoV-2 recombinant Spike Glycoprotein (S) <b>Indian variant</b> (x1mg)
	MT-25RBD	SARS-CoV-2 recombinant Receptor Binding Domain (BRD) (mammalian expression) (x1mg)

#### Bacterial expression

	MT-25C19NP	SARS-CoV-2 recombinant Nucleoprotein (N) (full sequence) (x1mg)
	MT-25C19NP.b.1.1.7	SARS-CoV-2 recombinant Nucleoprotein (N) <b>UK variant</b> (x1mg)
	MT-25C19NP.1.351	SARS-CoV-2 recombinant Nucleoprotein (N) <b>South African variant</b> (x1mg)
	MT-25C19NP.p.1	SARS-CoV-2 recombinant Nucleoprotein (N) <b>Brazilian variant</b> (x1mg)
	MT-25C19NP.b.1.617.2	SARS-CoV-2 recombinant Nucleoprotein (N) <b>Indian variant</b> (x1mg)

#### Antigens from other Coronavirus

	MT-25SANP	SARS Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)
	MT-25MENP	MERS Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)
	MT-25229NP	229E Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)
	MT-25OCNP	OC43 Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)
	MT-25HKNP	HKU1 Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)
	MT-25NLNP	NL63 Coronavirus recombinant Nucleoprotein (NP) (full sequence) (x1mg)

# Rapid Test


## For antigen detection

CerTest one-step immunochromatographic tests allow the **simultaneous qualitative detection** of SARS-CoV-2, Influenza type A, Influenza type B, and Respiratory Syncytial Virus (RSV) **antigens** in respiratory specimens from patients suspected of infection.

Symptoms related to COVID-19 infections can be confused with those of Influenza or even a common cold. A rapid test with differentiated detection of the multiple pathogens will reduce times and uncertainty on the initial screening of patients.



Results in  
**10**  
minutes



### Available products.




#### SARS-CoV-2

(20 test per kit)




#### SARS-CoV-2 + Flu A

(20 test per kit)



#### SARS-CoV-2 + Flu A + Flu B

(20 test per kit)



#### SARS-CoV-2 + Flu A + Flu B + RSV

(20 test per kit)

(\*) All tests include a Positive Control to verify the correct operation of the assay.

### Advantages:



#### Non-invasive diagnosis.

Nasopharyngeal swab sample.



#### No need for additional equipment.

All components included in the kit.



#### Low cost throughout the process.



#### Very simple use and interpretation.

More amount of analysis in the same time.



rapidtest@certest.es








## Real Time PCR Detection Kits

Real Time PCR tests designed for the identification of SARS-CoV-2 in respiratory samples from patients with signs and symptoms of COVID-19 infection.



### Available Kits

- Ref. NCO2      **SARS-CoV-2 (ORF1ab and N genes)**  
The diagnosis is performed by the amplification of a conserved region of *ORF1ab* and *N* genes for SARS-CoV-2 using specific primers and a fluorescent-labeled probe.
- Ref. NCO3      **SARS-CoV-2 (N1+N2)**  
The diagnosis is performed by the amplification of a conserved region of two conserved regions of *N* gene (*N1* and *N2*) for SARS-CoV-2 using specific primers and a fluorescent-labeled probe.
- Ref. CFR      **SARS-CoV-2, FLU & RSV**  
Qualitative detection of RNA from the SARS-CoV-2, Influenza A/B (Flu A/B) and/or Human Respiratory Syncytial Virus A/B (RSV A/B) in respiratory specimens.
- Ref. ABC      **Flu A, Flu B & SARS-CoV-2**  
Qualitative detection of RNA from the Influenza A (Flu A), Influenza B (Flu B) and/or SARS-CoV-2 from individuals suspected of respiratory infections.
- Ref. SUK1      **SARS-CoV-2 & UK Variant (S UK, S wt & N gene)**  
Qualitative detection of RNA from the SARS-CoV-2 and the HV 69/70 deletion of the S gene for SARS-CoV-2 associated to the SARS-CoV-2 VOC20212/01 (lineage B.1.1.7) variant and other variants in nasopharyngeal swabs from individuals suspected of SARS-CoV-2 infection disease (COVID-19.)
- Ref. SUK2      **SARS-CoV-2 del 69/70, ORF1ab & N genes**  
This test is intended for use as an aid in the diagnosis of SARS-CoV-2 as well as variants that carry the HV 69/70 deletion in combination with clinical and epidemiological risk factors.
- Ref. VAR      **SARS-CoV-2 Variant I**  
Qualitative RNA detection of genetic mutations in the S gene (E484K, K417N, K417T and N501Y) from SARS-CoV-2 positive nasopharyngeal samples.
- Ref. VAI      **SARS-CoV-2 Variant II**  
Qualitative detection of SARS-COV-2 RNA and the HV 69/70 deletion of the S gene for SARS-CoV-2 associated with the SARS-CoV-2 variant VOC-20212/01 (lineage B.1.1.7) in individuals with suspected COVID-19.



"Ready & Easy-to-use" kits.  
**Lyophilised product.**



**Transport and storage  
at room temperature.**



**Shelf-life: 24 months.**



[viasure@certest.es](mailto:viasure@certest.es)



<https://www.cerTEST.es/newsletter-subscription>  
Receive the latest news directly to your inbox!

# About CerTest Biotec, S.L.



**CerTest Biotec** is a European company **established in 2002** for the development and manufacturing of products for *in vitro* diagnosis of infectious diseases.

**Today, CerTest** is a global company structured around 5 business units offering one of the widest portfolios for human *in vitro* Diagnostic:

We base **the future** on a strong technical knowledge and expertise in the detection of human diseases.

Our last generation laboratories, state of the art technical equipment and skilled professionals are the keys for providing reliable solutions for the medical diagnostic professional.



**CerTest bioSCIENCE**



**BioSynProbes**



**CerTest Rapid Test**



**CerTest Turbilatex**



**VIASURE**



**CerTest CLIA**



**CerTest Vaccines**



Our products are available worldwide covering **more than 130 countries**.



**CerTest** offers a complete panel of reliable and highly sensitive diagnostic assays for the diagnosis of SARS-CoV-2 and other respiratory diseases.

We have more than 15 years of experience and dedication to the development of diagnostic assays for infectious diseases behind us.

**CerTest**  
BIOTEC

*One step ahead*

**CerTest Biotec, S.L.**

Pol. Industrial Río Gállego II · Calle J, Nº1  
50840, San Mateo de Gállego, Zaragoza (Spain)

Tel. (+34) 976 520 354

Fax (+34) 976 106 268

[certest@certest.es](mailto:certest@certest.es)

[www.certest.es](http://www.certest.es)



CerTest SARS-CoV-2 Catalogue/GEN-1021EN

Modification rights reserved. All rights reserved. © CerTest Biotec, S.L.  
The products, services and data set out in this document may suffer changes and/or variations on the texts and pictures shown.